NLS Biotech article

Anocca has announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.

All over the Nordics the innovative power is gearing up to put new products, therapies, and preventive measures on the market that will tackle Antimicrobial resistance (AMR) from various angles. 

Norwegian company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics – and the company is now ready to test its product in humans.

FinVector’s new production unit is set to become one of the world’s largest facilities for manufacturing gene-therapy treatments.

Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention. “Over the past two decades, genetic association studies have identified hundreds of genetic variations that affect body weight. Individuals who inherit many of these variations are more susceptible to gaining […]

For the second year running, Denmark’s biotech sector is awarded a global top three ranking by Scientific American Worldview and is praised for its generous public sector investment and speedy drug trial application process. Denmark takes the global top three spot in the 2016 Scientific American Worldview Scorecard, assessing countries worldwide according to their biotechnology […]